Biogen Inc vs Paycom Software Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Paycom Software Inc trades at $209.11 (market cap $9.57B). The key difference: Biogen Inc is far larger — about 3.1× Paycom Software Inc's market cap, and Paycom Software Inc pays a 0.71% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PAYC | |
|---|---|---|
Market Cap | $30.13B | $9.57B |
Sector | Health | Technology |
52-Week High | $216.63 | $233.89 |
52-Week Low | $128.93 | $113.59 |
Enterprise Value | $37.20B | $10.35B |
Dividend Yield | — | 0.71% |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →